Category: 4-1BB/GPC3

  • Pieris Out-licenses PRS-342 to Boston Pharmaceuticals for ~$363M

    Shots: Pieris to receive $10M upfront and is eligible to receive $353M in development, regulatory, and commercial based milestones along with royalties on sales of PRS-342. Pieris will also contribute an undisclosed amount for manufacturing activities Boston to get exclusive worldwide rights to develop PRS-342 and will be primarily responsible for the development of the […]